# Phaeno Thera

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/phaeno-thera

- Industry: Biotechnology
- Headquarters: Hangzhou, China
- Total disclosed funding: $15M
- Latest round: Series A (Aug 31, 2021)
- Investors on record: 5

## About

Based in Hangzhou, China and established in 2018, Phaeno Thera is a biomedical technology that focuses on the development of anti-infective drugs. The company has established an office and a biosafety secondary laboratory in Shanghai.

The company engages in the development of anti-infective drugs. Its main products include anti-human cytomegalovirus (HCMV) new drug HN0141, and anti-herpes simplex virus (HSV) new drug HN0037.

## Funding rounds

- Series A, Aug 31, 2021, $15M — Oriza Holdings, WinDigital Capital, BrightGene Bio-Medical Technology Co., Ltd., Laurel Venture
- Series A, Aug 16, 2019 — Oriza Holdings, Suzhou Yanying Investment Management

## Investors

- Oriza Holdings (https://capitalatlas.ai/funds/oriza-holdings) — Series A
- Suzhou Yanying Investment Management (https://capitalatlas.ai/funds/suzhou-yanying-investment-management) — Series A
- WinDigital Capital (https://capitalatlas.ai/funds/windigital-capital) — Series A
- BrightGene Bio-Medical Technology Co., Ltd. — Series A
- Laurel Venture (https://capitalatlas.ai/funds/laurel-venture) — Series A